Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. [electronic resource]
Producer: 20040517Description: 115-20 p. digitalISSN:- 1535-6108
- Animals
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- adverse effects
- Benzamides
- Cardiomyoplasty
- Colorectal Neoplasms -- drug therapy
- Cyclooxygenase 2
- Disease Models, Animal
- ErbB Receptors -- antagonists & inhibitors
- Gastrointestinal Diseases -- chemically induced
- Genes, abl -- physiology
- Genetic Engineering
- Humans
- Imatinib Mesylate
- Isoenzymes -- antagonists & inhibitors
- Membrane Proteins
- Mice
- Mice, Transgenic -- genetics
- Neoplasms -- drug therapy
- Piperazines -- adverse effects
- Prostaglandin-Endoperoxide Synthases -- metabolism
- Pyrimidines -- adverse effects
- Receptors, Platelet-Derived Growth Factor
- Receptors, Transforming Growth Factor beta -- antagonists & inhibitors
- Skin Abnormalities -- chemically induced
- Trastuzumab
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
There are no comments on this title.
Log in to your account to post a comment.